Bringing Alzheimer Disease Testing and Results Disclosure Into the 21st Century Cures Act.
作者信息
Largent Emily A, Bradbury Angela R
机构信息
Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Department of Medicine, Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.
出版信息
JAMA Neurol. 2022 Mar 1;79(3):219-220. doi: 10.1001/jamaneurol.2021.4851.
Abstract
摘要
相似文献
1
Bringing Alzheimer Disease Testing and Results Disclosure Into the 21st Century Cures Act.将阿尔茨海默病检测及结果披露纳入《21世纪治愈法案》。
JAMA Neurol. 2022 Mar 1;79(3):219-220. doi: 10.1001/jamaneurol.2021.4851.
2
Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.临床前阿尔茨海默病与电子健康记录：平衡保密性和护理。
Neurology. 2022 Nov 29;99(22):987-994. doi: 10.1212/WNL.0000000000201347. Epub 2022 Sep 30.
3
Enhancing Transparency at the US Food and Drug Administration: Moving Beyond the 21st Century Cures Act.提高美国食品药品监督管理局的透明度：超越《21世纪治愈法案》
JAMA. 2017 Apr 25;317(16):1621-1622. doi: 10.1001/jama.2017.2481.
4
The Ethics of Emergent Health Technologies: Implications of the 21st Century Cures Act for Nursing.新兴健康技术的伦理：《21世纪治愈法案》对护理的影响
Policy Polit Nurs Pract. 2020 Nov;21(4):195-201. doi: 10.1177/1527154420947028. Epub 2020 Aug 3.
5
An interview with Samuel Gandy, MD, PhD: Alzheimer's disease by Norman Sussman.医学博士、哲学博士塞缪尔·甘迪访谈：诺曼·萨斯曼谈阿尔茨海默病
CNS Spectr. 2009 May;14(5):248-51.
6
21st Century Cures Act and similar policy efforts: at what cost?《21世纪治愈法案》及类似政策举措：代价几何？
BMJ. 2015 Nov 23;351:h6122. doi: 10.1136/bmj.h6122.
7
Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers.阿尔茨海默病生物标志物检测与披露的科学、伦理及实践考量
Neurology. 2023 May 23;100(21):993-994. doi: 10.1212/WNL.0000000000207199. Epub 2023 Feb 15.
8
Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.21 世纪治愈法案对折点和商业抗菌药物敏感性测试系统的影响：进展与陷阱。
J Clin Microbiol. 2018 Apr 25;56(5). doi: 10.1128/JCM.00139-18. Print 2018 May.
9
The 21st Century Cures Act Implications for the Reduction of Racial Health Disparities in the US Criminal Justice System: a Public Health Approach.《21 世纪治愈法案》对减少美国刑事司法系统中种族健康差异的影响：公共卫生方法。
J Racial Ethn Health Disparities. 2018 Aug;5(4):885-893. doi: 10.1007/s40615-017-0435-0. Epub 2017 Nov 9.
10
Conflict-of-interest problems lead to policy changes.利益冲突问题导致政策变化。
Nat Med. 1999 Jul;5(7):717-8. doi: 10.1038/10421.
引用本文的文献
1
Applying recommendations for diagnostic disclosure of mild cognitive impairment and dementia: Practical guidance for clinicians.应用轻度认知障碍和痴呆诊断信息披露的建议：临床医生实用指南。
Alzheimers Dement. 2025 Jan;21(1):e14200. doi: 10.1002/alz.14200. Epub 2024 Dec 30.
2
Guidance for clinical management of pathogenic variant carriers at elevated genetic risk for ALS/FTD.肌萎缩侧索硬化症/额颞叶痴呆遗传风险升高的致病基因变异携带者临床管理指南
J Neurol Neurosurg Psychiatry. 2025 Jan 31;96(3). doi: 10.1136/jnnp-2024-334339.
3
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.考虑广泛应用阿尔茨海默病血液生物标志物。
Alzheimers Dement. 2024 Nov;20(11):8209-8215. doi: 10.1002/alz.14150. Epub 2024 Oct 6.
4
"There has to be more caring": patient and care partner experiences of the disclosure of amyloid-β PET scan results.“必须要有更多关怀”：患者及护理伙伴对淀粉样蛋白β正电子发射断层扫描结果披露的体验
Aging Ment Health. 2025 Jan;29(1):112-120. doi: 10.1080/13607863.2024.2371471. Epub 2024 Jun 26.
5
2024 Alzheimer's disease facts and figures.2024 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.
6
Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.阿尔茨海默病生物标志物检测及在疾病连续体中的结果披露
Neurology. 2023 May 23;100(21):1010-1019. doi: 10.1212/WNL.0000000000206891. Epub 2023 Jan 31.
7
Communicating and Using Dementia Risk Evidence.沟通和使用痴呆风险证据。
J Alzheimers Dis. 2022;90(3):933-944. doi: 10.3233/JAD-220722.
8
Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.临床前阿尔茨海默病与电子健康记录：平衡保密性和护理。
Neurology. 2022 Nov 29;99(22):987-994. doi: 10.1212/WNL.0000000000201347. Epub 2022 Sep 30.
9
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.超越披露：临床前阿尔茨海默病生物标志物检测中的护理阶段。
Alzheimers Dement. 2022 Oct;18(10):1969-1979. doi: 10.1002/alz.12620. Epub 2022 Feb 25.
本文引用的文献
1
Combining blood-based biomarkers to predict risk for Alzheimer's disease dementia.联合基于血液的生物标志物预测阿尔茨海默病痴呆风险。
Nat Aging. 2021 Jan;1(1):26-28. doi: 10.1038/s43587-020-00008-0.
2
Telemedicine and Medical Licensure - Potential Paths for Reform.远程医疗与医疗执照——改革的潜在途径
N Engl J Med. 2021 Feb 25;384(8):687-690. doi: 10.1056/NEJMp2031608. Epub 2021 Feb 20.
3
Private payer coverage policies for ApoE-e4 genetic testing.私人支付者对 ApoE-e4 基因检测的覆盖政策。
Genet Med. 2021 Apr;23(4):614-620. doi: 10.1038/s41436-020-01042-4. Epub 2021 Jan 8.
4
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.在接受阿杜卡单抗治疗的APOE ε4/ε4患者中出现的有症状的淀粉样蛋白相关成像异常。
Alzheimers Dement (Amst). 2020 Oct 9;12(1):e12101. doi: 10.1002/dad2.12101. eCollection 2020.
5
Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.认知正常成年人对淀粉样 PET 扫描结果披露的反应。
PLoS One. 2020 Feb 13;15(2):e0229137. doi: 10.1371/journal.pone.0229137. eCollection 2020.
6
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.阿尔茨海默病的遗传咨询和检测：美国医学遗传学学院和全国遗传咨询师协会的联合实践指南。
Genet Med. 2011 Jun;13(6):597-605. doi: 10.1097/GIM.0b013e31821d69b8.
Zotero 插件